It has been suggested that people with SMI may benefit from the use of GLP-1 agonists at an earlier stage due to barriers in accessing specialist weight management services
Tirzepatide improved this ratio somewhat through its dual-receptor action
Hashida, M
doi: 10.3389/fphar.2022.998179 Received 19 July 2022 Accepted 17 August 2022 Published 06 October 2022 Volume 13 - 2022 Edited by Tariq Ismail, Comsats University Islamabad, Pakistan Reviewed by Marcelino Maneiro, University of Santiago de Compostela, Spain Aisha Ayaz, Combined Military Hospital, Pakistan Updates Copyright 2022 Bulama, Nasiru, Bello, Abbas, Nasiru, Saidu, Chiroma, Mohd Moklas, Mat Taib, Waziri and Suleman
This might seem unnecessary, but its worth it